#METABOLOMICS WORKBENCH kuppal2_20190625_115502 DATATRACK_ID:1842					 STUDY_ID:ST001422 ANALYSIS_ID:AN002379 PROJECT_ID:PR000976
VERSION             	1				
CREATED_ON             	July 2, 2020, 2:40 pm
#PROJECT
PR:PROJECT_TITLE                 	Aspirin Metabolomics in Colorectal Cancer Chemoprevention - Blood (Part I)
PR:PROJECT_TYPE                  	NIH/NCI R01CA188038
PR:PROJECT_SUMMARY               	Substantial evidence supports the effectiveness of aspirin for cancer
PR:PROJECT_SUMMARY               	chemoprevention in addition to its well established role in cardiovascular
PR:PROJECT_SUMMARY               	protection. In recent meta-analyses of randomized controlled trials in human,
PR:PROJECT_SUMMARY               	daily aspirin use reduced incidence, metastasis and mortality from several
PR:PROJECT_SUMMARY               	common types of cancer, especially colorectal cancer. The mechanism(s) by which
PR:PROJECT_SUMMARY               	aspirin exerts an anticancer benefit is uncertain; numerous effects have been
PR:PROJECT_SUMMARY               	described involving both cyclooxygenase-dependent and -independent pathways. The
PR:PROJECT_SUMMARY               	goal of this research is to elucidate the key metabolic changes that are
PR:PROJECT_SUMMARY               	responsible for the anticancer effects of aspirin in humans using untargeted
PR:PROJECT_SUMMARY               	metabolomics analysis. Metabolomics, or global metabolite profiling, is an
PR:PROJECT_SUMMARY               	emerging discipline that has the potential to transform the study of
PR:PROJECT_SUMMARY               	pharmaceutical agents. Our innovative approach will use high-resolution mass
PR:PROJECT_SUMMARY               	spectroscopy to detect thousands of metabolites in blood plasma and normal colon
PR:PROJECT_SUMMARY               	mucosa biopsies that were collected from participants in the Aspirin/Folate
PR:PROJECT_SUMMARY               	Polyp Prevention Study, a randomized, double-blind, placebo-controlled trial of
PR:PROJECT_SUMMARY               	aspirin and/or folic acid supplementation for the prevention of colorectal
PR:PROJECT_SUMMARY               	adenomas. Participants in the trial were assigned with equal probability to
PR:PROJECT_SUMMARY               	three aspirin treatment arms (placebo, 81mg, or 325mg daily). Over the
PR:PROJECT_SUMMARY               	three-year period, 81mg/day of aspirin reduced the risk of adenomas, whereas the
PR:PROJECT_SUMMARY               	325 mg/day dose had less effect. The aims of the current proposal are to
PR:PROJECT_SUMMARY               	identify metabolomic signatures, including specific metabolites and metabolic
PR:PROJECT_SUMMARY               	pathways, that are associated with aspirin treatment in blood and normal colon
PR:PROJECT_SUMMARY               	mucosal tissue of participants after three years of randomized aspirin
PR:PROJECT_SUMMARY               	treatment; and then to assess the associations of these metabolic signatures
PR:PROJECT_SUMMARY               	with adenoma risk and whether they mediate the reductions in risk due to 81
PR:PROJECT_SUMMARY               	mg/day aspirin treatment. We will prioritize metabolites for study by evaluating
PR:PROJECT_SUMMARY               	metabolite levels in patients from the placebo and treatment arms while
PR:PROJECT_SUMMARY               	controlling the false discovery rate, use correlation analysis to enhance
PR:PROJECT_SUMMARY               	identification of relevant metabolic modules associated with these prioritized
PR:PROJECT_SUMMARY               	metabolites, and apply pathway mapping with post-hoc application of ion
PR:PROJECT_SUMMARY               	dissociation spectroscopy to representative metabolites to confirm pathway
PR:PROJECT_SUMMARY               	identification. Because aspirin is a multifunctional drug that is thought to
PR:PROJECT_SUMMARY               	modify numerous pathways with potential roles in carcinogenesis, a global
PR:PROJECT_SUMMARY               	discovery-based metabolomics approach is the best way to identify its key
PR:PROJECT_SUMMARY               	activities. The public health significance of this work is substantial because
PR:PROJECT_SUMMARY               	understanding the mechanism of aspirin's anticancer effects is key to optimizing
PR:PROJECT_SUMMARY               	its use and to the development of novel drugs targeting the metabolic pathways
PR:PROJECT_SUMMARY               	identified.
PR:INSTITUTE                     	Emory University Dept of Medicine
PR:DEPARTMENT                    	School of Medicine
PR:LABORATORY                    	Clinical Biomarkers Laboratory
PR:LAST_NAME                     	Tran
PR:FIRST_NAME                    	ViLinh
PR:ADDRESS                       	615 Michael St, suite 225
PR:EMAIL                         	vtran6@emory.edu
PR:PHONE                         	4047275091
PR:FUNDING_SOURCE                	NIH/NCI R01CA188038
#STUDY
ST:STUDY_TITLE                   	Aspirin Metabolomics in Colorectal Cancer Chemoprevention - blood (part-II)
ST:STUDY_SUMMARY                 	Substantial evidence supports the effectiveness of aspirin for cancer
ST:STUDY_SUMMARY                 	chemoprevention in addition to its well established role in cardiovascular
ST:STUDY_SUMMARY                 	protection. In recent meta-analyses of randomized controlled trials in human,
ST:STUDY_SUMMARY                 	daily aspirin use reduced incidence, metastasis and mortality from several
ST:STUDY_SUMMARY                 	common types of cancer, especially colorectal cancer. The mechanism(s) by which
ST:STUDY_SUMMARY                 	aspirin exerts an anticancer benefit is uncertain; numerous effects have been
ST:STUDY_SUMMARY                 	described involving both cyclooxygenase-dependent and -independent pathways. The
ST:STUDY_SUMMARY                 	goal of this research is to elucidate the key metabolic changes that are
ST:STUDY_SUMMARY                 	responsible for the anticancer effects of aspirin in humans using untargeted
ST:STUDY_SUMMARY                 	metabolomics analysis. Metabolomics, or global metabolite profiling, is an
ST:STUDY_SUMMARY                 	emerging discipline that has the potential to transform the study of
ST:STUDY_SUMMARY                 	pharmaceutical agents. Our innovative approach will use high-resolution mass
ST:STUDY_SUMMARY                 	spectroscopy to detect thousands of metabolites in blood plasma that were
ST:STUDY_SUMMARY                 	collected from participants in the Aspirin/Folate Polyp Prevention Study, a
ST:STUDY_SUMMARY                 	randomized, double-blind, placebo-controlled trial of aspirin for the prevention
ST:STUDY_SUMMARY                 	of colorectal adenomas. Participants in the trial were assigned with equal
ST:STUDY_SUMMARY                 	probability to three aspirin treatment arms (placebo, 81mg, or 325mg daily).
ST:STUDY_SUMMARY                 	Over the three-year period, 81mg/day of aspirin reduced the risk of adenomas,
ST:STUDY_SUMMARY                 	whereas the 325 mg/day dose had less effect. The aims of the current proposal
ST:STUDY_SUMMARY                 	are to identify metabolomic signatures, including specific metabolites and
ST:STUDY_SUMMARY                 	metabolic pathways, that are associated with aspirin treatment in blood of
ST:STUDY_SUMMARY                 	participants after three years of randomized aspirin treatment; and then to
ST:STUDY_SUMMARY                 	assess the associations of these metabolic signatures with adenoma risk and
ST:STUDY_SUMMARY                 	whether they mediate the reductions in risk due to 81 mg/day aspirin treatment.
ST:STUDY_SUMMARY                 	We will prioritize metabolites for study by evaluating metabolite levels in
ST:STUDY_SUMMARY                 	patients from the placebo and treatment arms while controlling the false
ST:STUDY_SUMMARY                 	discovery rate, use correlation analysis to enhance identification of relevant
ST:STUDY_SUMMARY                 	metabolic modules associated with these prioritized metabolites, and apply
ST:STUDY_SUMMARY                 	pathway mapping with post-hoc application of ion dissociation spectroscopy to
ST:STUDY_SUMMARY                 	representative metabolites to confirm pathway identification. Because aspirin is
ST:STUDY_SUMMARY                 	a multifunctional drug that is thought to modify numerous pathways with
ST:STUDY_SUMMARY                 	potential roles in carcinogenesis, a global discovery-based metabolomics
ST:STUDY_SUMMARY                 	approach is the best way to identify its key activities. The public health
ST:STUDY_SUMMARY                 	significance of this work is substantial because understanding the mechanism of
ST:STUDY_SUMMARY                 	aspirin's anticancer effects is key to optimizing its use and to the development
ST:STUDY_SUMMARY                 	of novel drugs targeting the metabolic pathways identified.
ST:INSTITUTE                     	Emory University
ST:DEPARTMENT                    	School of Medicine
ST:LABORATORY                    	Clincal Biomarkers Laboratory
ST:LAST_NAME                     	Uppal
ST:FIRST_NAME                    	Karan
ST:ADDRESS                       	615 Michael St, Suite 225
ST:EMAIL                         	kuppal2@emory.edu
ST:PHONE                         	(404) 727 5027
ST:TOTAL_SUBJECTS                	600
ST:STUDY_COMMENTS                	Aspirin Metabolomics Priority 1
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:AGE_OR_AGE_RANGE              	29-82
SU:GENDER                        	Male and female
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	Quality Control	nist_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160120_001
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_1a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160120_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000332_1	Sex:1 | Treatment:2	SubjectID=21115; RAW_FILE_NAME=VT_160120_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000306_1	Sex:1 | Treatment:-	SubjectID=20966; RAW_FILE_NAME=VT_160120_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000278_1	Sex:1 | Treatment:1	SubjectID=20753; RAW_FILE_NAME=VT_160120_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006690_1	Sex:1 | Treatment:-	SubjectID=71030; RAW_FILE_NAME=VT_160120_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000341_1	Sex:2 | Treatment:-	SubjectID=40553; RAW_FILE_NAME=VT_160120_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000293_1	Sex:1 | Treatment:-	SubjectID=20843; RAW_FILE_NAME=VT_160120_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000279_1	Sex:1 | Treatment:1	SubjectID=20753; RAW_FILE_NAME=VT_160120_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000333_1	Sex:1 | Treatment:-	SubjectID=21160; RAW_FILE_NAME=VT_160120_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000335_1	Sex:1 | Treatment:2	SubjectID=21181; RAW_FILE_NAME=VT_160120_061
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001464_1	Sex:2 | Treatment:2	SubjectID=40586; RAW_FILE_NAME=VT_160120_067
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_1b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160120_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000292_1	Sex:1 | Treatment:-	SubjectID=20843; RAW_FILE_NAME=VT_160120_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000347_1	Sex:2 | Treatment:2	SubjectID=40586; RAW_FILE_NAME=VT_160120_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000343_1	Sex:2 | Treatment:-	SubjectID=40553; RAW_FILE_NAME=VT_160120_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000213_1	Sex:1 | Treatment:-	SubjectID=71030; RAW_FILE_NAME=VT_160120_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000331_1	Sex:1 | Treatment:2	SubjectID=21115; RAW_FILE_NAME=VT_160120_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000334_1	Sex:1 | Treatment:-	SubjectID=21160; RAW_FILE_NAME=VT_160120_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000307_1	Sex:1 | Treatment:-	SubjectID=20966; RAW_FILE_NAME=VT_160120_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005976_1	Sex:1 | Treatment:1	SubjectID=40621; RAW_FILE_NAME=VT_160120_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000349_1	Sex:1 | Treatment:1	SubjectID=40621; RAW_FILE_NAME=VT_160120_127
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000944_1	Sex:1 | Treatment:2	SubjectID=21181; RAW_FILE_NAME=VT_160120_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_1c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160120_139
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_2a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160121_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000417_1	Sex:2 | Treatment:-	SubjectID=20068; RAW_FILE_NAME=VT_160121_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000406_1	Sex:1 | Treatment:2	SubjectID=41060; RAW_FILE_NAME=VT_160121_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000394_1	Sex:1 | Treatment:-	SubjectID=40979; RAW_FILE_NAME=VT_160121_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40016031_1	Sex:1 | Treatment:2	SubjectID=41060; RAW_FILE_NAME=VT_160121_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000381_1	Sex:2 | Treatment:1	SubjectID=40867; RAW_FILE_NAME=VT_160121_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000434_1	Sex:1 | Treatment:2	SubjectID=20215; RAW_FILE_NAME=VT_160121_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000439_1	Sex:2 | Treatment:1	SubjectID=20259; RAW_FILE_NAME=VT_160121_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000877_1	Sex:2 | Treatment:-	SubjectID=20068; RAW_FILE_NAME=VT_160121_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000395_1	Sex:1 | Treatment:-	SubjectID=40979; RAW_FILE_NAME=VT_160121_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000433_1	Sex:1 | Treatment:2	SubjectID=20215; RAW_FILE_NAME=VT_160121_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_2b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160121_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000440_1	Sex:2 | Treatment:1	SubjectID=20259; RAW_FILE_NAME=VT_160121_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000408_1	Sex:1 | Treatment:2	SubjectID=41071; RAW_FILE_NAME=VT_160121_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000380_1	Sex:2 | Treatment:1	SubjectID=40867; RAW_FILE_NAME=VT_160121_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40016032_1	Sex:1 | Treatment:2	SubjectID=41071; RAW_FILE_NAME=VT_160121_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000468_1	Sex:2 | Treatment:-	SubjectID=20518; RAW_FILE_NAME=VT_160121_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005553_1	Sex:2 | Treatment:-	SubjectID=20518; RAW_FILE_NAME=VT_160121_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006806_1	Sex:1 | Treatment:2	SubjectID=40799; RAW_FILE_NAME=VT_160121_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000370_1	Sex:1 | Treatment:-	SubjectID=40788; RAW_FILE_NAME=VT_160121_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000369_1	Sex:1 | Treatment:-	SubjectID=40788; RAW_FILE_NAME=VT_160121_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000371_1	Sex:1 | Treatment:2	SubjectID=40799; RAW_FILE_NAME=VT_160121_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_2c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160121_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_3a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160122_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105580_1	Sex:1 | Treatment:2	SubjectID=30394; RAW_FILE_NAME=VT_160122_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105659_1	Sex:1 | Treatment:2	SubjectID=60702; RAW_FILE_NAME=VT_160122_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105537_1	Sex:2 | Treatment:-	SubjectID=22070; RAW_FILE_NAME=VT_160122_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105600_1	Sex:2 | Treatment:-	SubjectID=30541; RAW_FILE_NAME=VT_160122_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006455_1	Sex:1 | Treatment:2	SubjectID=60702; RAW_FILE_NAME=VT_160122_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000471_1	Sex:2 | Treatment:-	SubjectID=20530; RAW_FILE_NAME=VT_160122_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105548_1	Sex:2 | Treatment:1	SubjectID=30115; RAW_FILE_NAME=VT_160122_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105504_1	Sex:2 | Treatment:-	SubjectID=21822; RAW_FILE_NAME=VT_160122_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105689_1	Sex:1 | Treatment:1	SubjectID=60959; RAW_FILE_NAME=VT_160122_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005835_1	Sex:2 | Treatment:-	SubjectID=30541; RAW_FILE_NAME=VT_160122_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_3b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160122_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005737_1	Sex:2 | Treatment:1	SubjectID=30115; RAW_FILE_NAME=VT_160122_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105581_1	Sex:1 | Treatment:2	SubjectID=30394; RAW_FILE_NAME=VT_160122_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000472_1	Sex:2 | Treatment:-	SubjectID=20530; RAW_FILE_NAME=VT_160122_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005828_1	Sex:1 | Treatment:2	SubjectID=22048; RAW_FILE_NAME=VT_160122_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000482_1	Sex:1 | Treatment:1	SubjectID=20595; RAW_FILE_NAME=VT_160122_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105534_1	Sex:1 | Treatment:2	SubjectID=22048; RAW_FILE_NAME=VT_160122_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005702_1	Sex:2 | Treatment:-	SubjectID=21822; RAW_FILE_NAME=VT_160122_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015140_1	Sex:1 | Treatment:1	SubjectID=20595; RAW_FILE_NAME=VT_160122_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105536_1	Sex:2 | Treatment:-	SubjectID=22070; RAW_FILE_NAME=VT_160122_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105690_1	Sex:1 | Treatment:1	SubjectID=60959; RAW_FILE_NAME=VT_160122_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_3c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160122_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_4a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160123_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105883_1	Sex:1 | Treatment:-	SubjectID=21394; RAW_FILE_NAME=VT_160123_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006950_1	Sex:2 | Treatment:2	SubjectID=80590; RAW_FILE_NAME=VT_160123_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105963_1	Sex:2 | Treatment:2	SubjectID=80590; RAW_FILE_NAME=VT_160123_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106004_1	Sex:1 | Treatment:2	SubjectID=80994; RAW_FILE_NAME=VT_160123_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105974_1	Sex:1 | Treatment:-	SubjectID=80691; RAW_FILE_NAME=VT_160123_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105923_1	Sex:1 | Treatment:2	SubjectID=21697; RAW_FILE_NAME=VT_160123_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106005_1	Sex:1 | Treatment:2	SubjectID=80994; RAW_FILE_NAME=VT_160123_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106051_1	Sex:1 | Treatment:-	SubjectID=10258; RAW_FILE_NAME=VT_160123_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001704_1	Sex:1 | Treatment:-	SubjectID=60465; RAW_FILE_NAME=VT_160123_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105999_1	Sex:1 | Treatment:1	SubjectID=80939; RAW_FILE_NAME=VT_160123_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_4b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160123_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000771_1	Sex:1 | Treatment:-	SubjectID=10258; RAW_FILE_NAME=VT_160123_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106045_1	Sex:1 | Treatment:1	SubjectID=10203; RAW_FILE_NAME=VT_160123_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015928_1	Sex:1 | Treatment:1	SubjectID=10203; RAW_FILE_NAME=VT_160123_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106002_1	Sex:1 | Treatment:2	SubjectID=80972; RAW_FILE_NAME=VT_160123_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006629_1	Sex:1 | Treatment:2	SubjectID=80972; RAW_FILE_NAME=VT_160123_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105998_1	Sex:1 | Treatment:1	SubjectID=80939; RAW_FILE_NAME=VT_160123_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105776_1	Sex:1 | Treatment:-	SubjectID=60465; RAW_FILE_NAME=VT_160123_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105973_1	Sex:1 | Treatment:-	SubjectID=80691; RAW_FILE_NAME=VT_160123_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105924_1	Sex:1 | Treatment:2	SubjectID=21697; RAW_FILE_NAME=VT_160123_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105884_1	Sex:1 | Treatment:-	SubjectID=21394; RAW_FILE_NAME=VT_160123_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_4c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160123_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_5a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160125_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106476_1	Sex:1 | Treatment:-	SubjectID=41824; RAW_FILE_NAME=VT_160125_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106136_1	Sex:2 | Treatment:2	SubjectID=90660; RAW_FILE_NAME=VT_160125_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106066_1	Sex:2 | Treatment:1	SubjectID=10392; RAW_FILE_NAME=VT_160125_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106529_1	Sex:1 | Treatment:2	SubjectID=50410; RAW_FILE_NAME=VT_160125_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106019_1	Sex:1 | Treatment:-	SubjectID=10326; RAW_FILE_NAME=VT_160125_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106173_1	Sex:2 | Treatment:2	SubjectID=91212; RAW_FILE_NAME=VT_160125_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106057_1	Sex:1 | Treatment:-	SubjectID=10326; RAW_FILE_NAME=VT_160125_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106065_1	Sex:2 | Treatment:1	SubjectID=10392; RAW_FILE_NAME=VT_160125_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106133_1	Sex:2 | Treatment:-	SubjectID=90659; RAW_FILE_NAME=VT_160125_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106172_1	Sex:2 | Treatment:2	SubjectID=91212; RAW_FILE_NAME=VT_160125_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_5b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160125_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106475_1	Sex:1 | Treatment:-	SubjectID=41824; RAW_FILE_NAME=VT_160125_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106135_1	Sex:2 | Treatment:2	SubjectID=90660; RAW_FILE_NAME=VT_160125_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106495_1	Sex:1 | Treatment:2	SubjectID=50128; RAW_FILE_NAME=VT_160125_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106635_1	Sex:1 | Treatment:1	SubjectID=51353; RAW_FILE_NAME=VT_160125_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006227_1	Sex:1 | Treatment:2	SubjectID=50128; RAW_FILE_NAME=VT_160125_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015882_1	Sex:2 | Treatment:-	SubjectID=90659; RAW_FILE_NAME=VT_160125_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106530_1	Sex:1 | Treatment:2	SubjectID=50410; RAW_FILE_NAME=VT_160125_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106634_1	Sex:1 | Treatment:1	SubjectID=51353; RAW_FILE_NAME=VT_160125_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106587_1	Sex:2 | Treatment:2	SubjectID=61108; RAW_FILE_NAME=VT_160125_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006268_1	Sex:2 | Treatment:2	SubjectID=61108; RAW_FILE_NAME=VT_160125_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_5c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160125_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_6a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160126_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006083_1	Sex:1 | Treatment:1	SubjectID=41374; RAW_FILE_NAME=VT_160126_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106227_1	Sex:1 | Treatment:-	SubjectID=41510; RAW_FILE_NAME=VT_160126_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005940_1	Sex:2 | Treatment:2	SubjectID=41140; RAW_FILE_NAME=VT_160126_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106231_1	Sex:2 | Treatment:-	SubjectID=41543; RAW_FILE_NAME=VT_160126_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106226_1	Sex:1 | Treatment:-	SubjectID=41510; RAW_FILE_NAME=VT_160126_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001533_1	Sex:1 | Treatment:-	SubjectID=41600; RAW_FILE_NAME=VT_160126_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106178_1	Sex:2 | Treatment:1	SubjectID=91245; RAW_FILE_NAME=VT_160126_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001152_1	Sex:2 | Treatment:1	SubjectID=91245; RAW_FILE_NAME=VT_160126_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015174_1	Sex:1 | Treatment:1	SubjectID=11530; RAW_FILE_NAME=VT_160126_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106251_1	Sex:2 | Treatment:1	SubjectID=41677; RAW_FILE_NAME=VT_160126_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_6b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160126_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006464_1	Sex:2 | Treatment:-	SubjectID=70095; RAW_FILE_NAME=VT_160126_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106301_1	Sex:1 | Treatment:1	SubjectID=11530; RAW_FILE_NAME=VT_160126_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005972_1	Sex:1 | Treatment:2	SubjectID=41611; RAW_FILE_NAME=VT_160126_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106336_1	Sex:2 | Treatment:-	SubjectID=70095; RAW_FILE_NAME=VT_160126_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006811_1	Sex:2 | Treatment:-	SubjectID=41543; RAW_FILE_NAME=VT_160126_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106241_1	Sex:1 | Treatment:-	SubjectID=41600; RAW_FILE_NAME=VT_160126_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106182_1	Sex:2 | Treatment:2	SubjectID=41140; RAW_FILE_NAME=VT_160126_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106243_1	Sex:1 | Treatment:2	SubjectID=41611; RAW_FILE_NAME=VT_160126_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106211_1	Sex:1 | Treatment:1	SubjectID=41374; RAW_FILE_NAME=VT_160126_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106252_1	Sex:2 | Treatment:1	SubjectID=41677; RAW_FILE_NAME=VT_160126_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_6c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160126_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_7a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160127_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106415_1	Sex:2 | Treatment:-	SubjectID=30866; RAW_FILE_NAME=VT_160127_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106409_1	Sex:1 | Treatment:1	SubjectID=30833; RAW_FILE_NAME=VT_160127_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106418_1	Sex:1 | Treatment:2	SubjectID=30888; RAW_FILE_NAME=VT_160127_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106416_1	Sex:1 | Treatment:-	SubjectID=30877; RAW_FILE_NAME=VT_160127_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106402_1	Sex:1 | Treatment:2	SubjectID=30800; RAW_FILE_NAME=VT_160127_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106350_1	Sex:2 | Treatment:2	SubjectID=70264; RAW_FILE_NAME=VT_160127_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106417_1	Sex:1 | Treatment:-	SubjectID=30877; RAW_FILE_NAME=VT_160127_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106414_1	Sex:2 | Treatment:-	SubjectID=30866; RAW_FILE_NAME=VT_160127_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106419_1	Sex:1 | Treatment:2	SubjectID=30888; RAW_FILE_NAME=VT_160127_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106383_1	Sex:1 | Treatment:2	SubjectID=70556; RAW_FILE_NAME=VT_160127_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_7b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160127_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106352_1	Sex:1 | Treatment:2	SubjectID=70275; RAW_FILE_NAME=VT_160127_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106382_1	Sex:1 | Treatment:2	SubjectID=70556; RAW_FILE_NAME=VT_160127_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106376_1	Sex:2 | Treatment:-	SubjectID=70501; RAW_FILE_NAME=VT_160127_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006697_1	Sex:2 | Treatment:2	SubjectID=70264; RAW_FILE_NAME=VT_160127_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106353_1	Sex:1 | Treatment:2	SubjectID=70275; RAW_FILE_NAME=VT_160127_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106425_1	Sex:1 | Treatment:2	SubjectID=30912; RAW_FILE_NAME=VT_160127_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005863_1	Sex:1 | Treatment:2	SubjectID=30800; RAW_FILE_NAME=VT_160127_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005826_1	Sex:1 | Treatment:1	SubjectID=30833; RAW_FILE_NAME=VT_160127_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006551_1	Sex:2 | Treatment:-	SubjectID=70501; RAW_FILE_NAME=VT_160127_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106424_1	Sex:1 | Treatment:2	SubjectID=30912; RAW_FILE_NAME=VT_160127_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_7c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160127_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_8a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160128_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106460_1	Sex:1 | Treatment:1	SubjectID=31182; RAW_FILE_NAME=VT_160128_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006968_1	Sex:2 | Treatment:1	SubjectID=90121; RAW_FILE_NAME=VT_160128_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000604_1	Sex:2 | Treatment:1	SubjectID=40171; RAW_FILE_NAME=VT_160128_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106454_1	Sex:1 | Treatment:-	SubjectID=31127; RAW_FILE_NAME=VT_160128_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106452_1	Sex:1 | Treatment:-	SubjectID=31116; RAW_FILE_NAME=VT_160128_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106456_1	Sex:2 | Treatment:-	SubjectID=31138; RAW_FILE_NAME=VT_160128_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001420_1	Sex:1 | Treatment:2	SubjectID=40138; RAW_FILE_NAME=VT_160128_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015709_1	Sex:2 | Treatment:-	SubjectID=31138; RAW_FILE_NAME=VT_160128_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000554_1	Sex:2 | Treatment:1	SubjectID=90121; RAW_FILE_NAME=VT_160128_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106453_1	Sex:1 | Treatment:-	SubjectID=31116; RAW_FILE_NAME=VT_160128_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_8b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160128_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000514_1	Sex:1 | Treatment:1	SubjectID=81031; RAW_FILE_NAME=VT_160128_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015708_1	Sex:1 | Treatment:-	SubjectID=31127; RAW_FILE_NAME=VT_160128_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015811_1	Sex:1 | Treatment:1	SubjectID=81031; RAW_FILE_NAME=VT_160128_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106435_1	Sex:2 | Treatment:2	SubjectID=30967; RAW_FILE_NAME=VT_160128_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000603_1	Sex:2 | Treatment:1	SubjectID=40171; RAW_FILE_NAME=VT_160128_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000598_1	Sex:1 | Treatment:2	SubjectID=40138; RAW_FILE_NAME=VT_160128_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106434_1	Sex:2 | Treatment:2	SubjectID=30967; RAW_FILE_NAME=VT_160128_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106461_1	Sex:1 | Treatment:1	SubjectID=31182; RAW_FILE_NAME=VT_160128_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106428_1	Sex:1 | Treatment:-	SubjectID=30934; RAW_FILE_NAME=VT_160128_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106429_1	Sex:1 | Treatment:-	SubjectID=30934; RAW_FILE_NAME=VT_160128_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_8c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160128_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_9a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160129_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001677_1	Sex:1 | Treatment:1	SubjectID=10853; RAW_FILE_NAME=VT_160129_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001459_1	Sex:1 | Treatment:1	SubjectID=40509; RAW_FILE_NAME=VT_160129_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000682_1	Sex:1 | Treatment:-	SubjectID=50598; RAW_FILE_NAME=VT_160129_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001816_1	Sex:2 | Treatment:2	SubjectID=81075; RAW_FILE_NAME=VT_160129_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001180_1	Sex:2 | Treatment:2	SubjectID=81075; RAW_FILE_NAME=VT_160129_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001752_1	Sex:1 | Treatment:1	SubjectID=80737; RAW_FILE_NAME=VT_160129_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001163_1	Sex:2 | Treatment:1	SubjectID=80816; RAW_FILE_NAME=VT_160129_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000612_1	Sex:1 | Treatment:1	SubjectID=40217; RAW_FILE_NAME=VT_160129_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000819_1	Sex:1 | Treatment:1	SubjectID=10853; RAW_FILE_NAME=VT_160129_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015805_1	Sex:1 | Treatment:1	SubjectID=80737; RAW_FILE_NAME=VT_160129_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_9b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160129_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001800_1	Sex:1 | Treatment:1	SubjectID=90244; RAW_FILE_NAME=VT_160129_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000683_1	Sex:1 | Treatment:-	SubjectID=50598; RAW_FILE_NAME=VT_160129_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001778_1	Sex:2 | Treatment:1	SubjectID=90010; RAW_FILE_NAME=VT_160129_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000611_1	Sex:1 | Treatment:1	SubjectID=40217; RAW_FILE_NAME=VT_160129_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006664_1	Sex:2 | Treatment:1	SubjectID=90010; RAW_FILE_NAME=VT_160129_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001762_1	Sex:2 | Treatment:1	SubjectID=80816; RAW_FILE_NAME=VT_160129_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001205_1	Sex:1 | Treatment:-	SubjectID=80636; RAW_FILE_NAME=VT_160129_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000574_1	Sex:1 | Treatment:1	SubjectID=90244; RAW_FILE_NAME=VT_160129_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000654_1	Sex:1 | Treatment:1	SubjectID=40509; RAW_FILE_NAME=VT_160129_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001747_1	Sex:1 | Treatment:-	SubjectID=80636; RAW_FILE_NAME=VT_160129_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_9c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160129_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_10a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160130_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001862_1	Sex:2 | Treatment:1	SubjectID=80568; RAW_FILE_NAME=VT_160130_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001239_1	Sex:2 | Treatment:-	SubjectID=80344; RAW_FILE_NAME=VT_160130_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001901_1	Sex:1 | Treatment:-	SubjectID=90446; RAW_FILE_NAME=VT_160130_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001853_1	Sex:2 | Treatment:-	SubjectID=80490; RAW_FILE_NAME=VT_160130_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105958_1	Sex:2 | Treatment:1	SubjectID=80568; RAW_FILE_NAME=VT_160130_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006946_1	Sex:1 | Treatment:-	SubjectID=90446; RAW_FILE_NAME=VT_160130_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106568_1	Sex:2 | Treatment:1	SubjectID=91470; RAW_FILE_NAME=VT_160130_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001871_1	Sex:1 | Treatment:-	SubjectID=91458; RAW_FILE_NAME=VT_160130_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001884_1	Sex:1 | Treatment:1	SubjectID=91560; RAW_FILE_NAME=VT_160130_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001192_1	Sex:2 | Treatment:-	SubjectID=80490; RAW_FILE_NAME=VT_160130_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_10b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160130_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105962_1	Sex:1 | Treatment:-	SubjectID=80580; RAW_FILE_NAME=VT_160130_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001835_1	Sex:2 | Treatment:-	SubjectID=80344; RAW_FILE_NAME=VT_160130_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001187_1	Sex:2 | Treatment:-	SubjectID=80412; RAW_FILE_NAME=VT_160130_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015200_1	Sex:1 | Treatment:-	SubjectID=91458; RAW_FILE_NAME=VT_160130_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001844_1	Sex:2 | Treatment:-	SubjectID=80412; RAW_FILE_NAME=VT_160130_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001876_1	Sex:2 | Treatment:1	SubjectID=91470; RAW_FILE_NAME=VT_160130_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015193_1	Sex:1 | Treatment:1	SubjectID=91560; RAW_FILE_NAME=VT_160130_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001849_1	Sex:1 | Treatment:1	SubjectID=80467; RAW_FILE_NAME=VT_160130_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001190_1	Sex:1 | Treatment:1	SubjectID=80467; RAW_FILE_NAME=VT_160130_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001867_1	Sex:1 | Treatment:-	SubjectID=80580; RAW_FILE_NAME=VT_160130_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_10c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160130_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_11a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160201_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106156_1	Sex:2 | Treatment:2	SubjectID=90793; RAW_FILE_NAME=VT_160201_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106816_1	Sex:1 | Treatment:2	SubjectID=91032; RAW_FILE_NAME=VT_160201_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001966_1	Sex:1 | Treatment:1	SubjectID=90962; RAW_FILE_NAME=VT_160201_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006945_1	Sex:1 | Treatment:-	SubjectID=90490; RAW_FILE_NAME=VT_160201_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007084_1	Sex:1 | Treatment:2	SubjectID=91346; RAW_FILE_NAME=VT_160201_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007018_1	Sex:2 | Treatment:1	SubjectID=91043; RAW_FILE_NAME=VT_160201_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001937_1	Sex:2 | Treatment:1	SubjectID=90738; RAW_FILE_NAME=VT_160201_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002007_1	Sex:1 | Treatment:2	SubjectID=91346; RAW_FILE_NAME=VT_160201_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001910_1	Sex:1 | Treatment:-	SubjectID=90490; RAW_FILE_NAME=VT_160201_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006979_1	Sex:2 | Treatment:1	SubjectID=90951; RAW_FILE_NAME=VT_160201_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_11b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160201_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106181_1	Sex:2 | Treatment:2	SubjectID=91234; RAW_FILE_NAME=VT_160201_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001944_1	Sex:2 | Treatment:2	SubjectID=90793; RAW_FILE_NAME=VT_160201_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001976_1	Sex:1 | Treatment:2	SubjectID=91032; RAW_FILE_NAME=VT_160201_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001975_1	Sex:2 | Treatment:1	SubjectID=91043; RAW_FILE_NAME=VT_160201_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001964_1	Sex:2 | Treatment:1	SubjectID=90951; RAW_FILE_NAME=VT_160201_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001996_1	Sex:2 | Treatment:2	SubjectID=91234; RAW_FILE_NAME=VT_160201_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001962_1	Sex:1 | Treatment:2	SubjectID=90940; RAW_FILE_NAME=VT_160201_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106146_1	Sex:2 | Treatment:1	SubjectID=90738; RAW_FILE_NAME=VT_160201_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006978_1	Sex:1 | Treatment:2	SubjectID=90940; RAW_FILE_NAME=VT_160201_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007016_1	Sex:1 | Treatment:1	SubjectID=90962; RAW_FILE_NAME=VT_160201_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_11c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160201_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_12a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160202_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000243_1	Sex:1 | Treatment:2	SubjectID=80063; RAW_FILE_NAME=VT_160202_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002108_1	Sex:1 | Treatment:2	SubjectID=80063; RAW_FILE_NAME=VT_160202_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006635_1	Sex:1 | Treatment:2	SubjectID=61119; RAW_FILE_NAME=VT_160202_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105686_1	Sex:2 | Treatment:1	SubjectID=60915; RAW_FILE_NAME=VT_160202_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007082_1	Sex:1 | Treatment:1	SubjectID=91414; RAW_FILE_NAME=VT_160202_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002033_1	Sex:2 | Treatment:1	SubjectID=60915; RAW_FILE_NAME=VT_160202_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002041_1	Sex:1 | Treatment:-	SubjectID=60981; RAW_FILE_NAME=VT_160202_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002040_1	Sex:1 | Treatment:1	SubjectID=60970; RAW_FILE_NAME=VT_160202_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002134_1	Sex:1 | Treatment:2	SubjectID=61119; RAW_FILE_NAME=VT_160202_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007105_1	Sex:1 | Treatment:-	SubjectID=91390; RAW_FILE_NAME=VT_160202_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_12b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160202_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006506_1	Sex:1 | Treatment:-	SubjectID=61018; RAW_FILE_NAME=VT_160202_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002012_1	Sex:1 | Treatment:-	SubjectID=91390; RAW_FILE_NAME=VT_160202_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006634_1	Sex:1 | Treatment:1	SubjectID=60970; RAW_FILE_NAME=VT_160202_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002044_1	Sex:1 | Treatment:-	SubjectID=61018; RAW_FILE_NAME=VT_160202_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001687_1	Sex:1 | Treatment:-	SubjectID=80142; RAW_FILE_NAME=VT_160202_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002047_1	Sex:2 | Treatment:2	SubjectID=61040; RAW_FILE_NAME=VT_160202_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002016_1	Sex:1 | Treatment:1	SubjectID=91414; RAW_FILE_NAME=VT_160202_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015354_1	Sex:2 | Treatment:2	SubjectID=61040; RAW_FILE_NAME=VT_160202_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105696_1	Sex:1 | Treatment:-	SubjectID=60981; RAW_FILE_NAME=VT_160202_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002121_1	Sex:1 | Treatment:-	SubjectID=80142; RAW_FILE_NAME=VT_160202_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_12c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160202_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_13a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160203_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002177_1	Sex:2 | Treatment:-	SubjectID=61499; RAW_FILE_NAME=VT_160203_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001366_1	Sex:2 | Treatment:1	SubjectID=70387; RAW_FILE_NAME=VT_160203_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015952_1	Sex:2 | Treatment:1	SubjectID=61545; RAW_FILE_NAME=VT_160203_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106680_1	Sex:2 | Treatment:-	SubjectID=61499; RAW_FILE_NAME=VT_160203_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006375_1	Sex:2 | Treatment:2	SubjectID=61556; RAW_FILE_NAME=VT_160203_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002188_1	Sex:1 | Treatment:1	SubjectID=61578; RAW_FILE_NAME=VT_160203_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40020696_1	Sex:2 | Treatment:-	SubjectID=61411; RAW_FILE_NAME=VT_160203_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002151_1	Sex:1 | Treatment:2	SubjectID=61242; RAW_FILE_NAME=VT_160203_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002240_1	Sex:2 | Treatment:1	SubjectID=70657; RAW_FILE_NAME=VT_160203_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002215_1	Sex:1 | Treatment:1	SubjectID=70398; RAW_FILE_NAME=VT_160203_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_13b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160203_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002213_1	Sex:2 | Treatment:1	SubjectID=70387; RAW_FILE_NAME=VT_160203_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002184_1	Sex:2 | Treatment:2	SubjectID=61556; RAW_FILE_NAME=VT_160203_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002169_1	Sex:2 | Treatment:-	SubjectID=61411; RAW_FILE_NAME=VT_160203_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002182_1	Sex:2 | Treatment:1	SubjectID=61545; RAW_FILE_NAME=VT_160203_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006386_1	Sex:1 | Treatment:1	SubjectID=61578; RAW_FILE_NAME=VT_160203_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006639_1	Sex:1 | Treatment:2	SubjectID=61635; RAW_FILE_NAME=VT_160203_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106648_1	Sex:1 | Treatment:2	SubjectID=61242; RAW_FILE_NAME=VT_160203_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002199_1	Sex:1 | Treatment:2	SubjectID=61635; RAW_FILE_NAME=VT_160203_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106395_1	Sex:2 | Treatment:1	SubjectID=70657; RAW_FILE_NAME=VT_160203_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006700_1	Sex:1 | Treatment:1	SubjectID=70398; RAW_FILE_NAME=VT_160203_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_13c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160203_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_14a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160204_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002307_1	Sex:2 | Treatment:2	SubjectID=70152; RAW_FILE_NAME=VT_160204_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001335_1	Sex:2 | Treatment:2	SubjectID=70141; RAW_FILE_NAME=VT_160204_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002355_1	Sex:1 | Treatment:-	SubjectID=40687; RAW_FILE_NAME=VT_160204_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001338_1	Sex:2 | Treatment:2	SubjectID=70152; RAW_FILE_NAME=VT_160204_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000652_1	Sex:1 | Treatment:2	SubjectID=40496; RAW_FILE_NAME=VT_160204_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001353_1	Sex:1 | Treatment:2	SubjectID=70242; RAW_FILE_NAME=VT_160204_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002253_1	Sex:2 | Treatment:2	SubjectID=70758; RAW_FILE_NAME=VT_160204_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001398_1	Sex:2 | Treatment:1	SubjectID=70815; RAW_FILE_NAME=VT_160204_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002340_1	Sex:1 | Treatment:2	SubjectID=40496; RAW_FILE_NAME=VT_160204_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006809_1	Sex:2 | Treatment:-	SubjectID=41500; RAW_FILE_NAME=VT_160204_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_14b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160204_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106234_1	Sex:1 | Treatment:1	SubjectID=41554; RAW_FILE_NAME=VT_160204_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002287_1	Sex:1 | Treatment:2	SubjectID=70040; RAW_FILE_NAME=VT_160204_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002379_1	Sex:1 | Treatment:1	SubjectID=41554; RAW_FILE_NAME=VT_160204_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002305_1	Sex:2 | Treatment:2	SubjectID=70141; RAW_FILE_NAME=VT_160204_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001321_1	Sex:1 | Treatment:2	SubjectID=70040; RAW_FILE_NAME=VT_160204_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002377_1	Sex:2 | Treatment:-	SubjectID=41500; RAW_FILE_NAME=VT_160204_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001470_1	Sex:1 | Treatment:-	SubjectID=40687; RAW_FILE_NAME=VT_160204_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000005_1	Sex:2 | Treatment:2	SubjectID=70758; RAW_FILE_NAME=VT_160204_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002258_1	Sex:2 | Treatment:1	SubjectID=70815; RAW_FILE_NAME=VT_160204_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002319_1	Sex:1 | Treatment:2	SubjectID=70242; RAW_FILE_NAME=VT_160204_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_14c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160204_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_15a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160205_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002456_1	Sex:1 | Treatment:1	SubjectID=50442; RAW_FILE_NAME=VT_160205_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006193_1	Sex:1 | Treatment:-	SubjectID=50486; RAW_FILE_NAME=VT_160205_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002465_1	Sex:2 | Treatment:2	SubjectID=50554; RAW_FILE_NAME=VT_160205_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106210_1	Sex:2 | Treatment:-	SubjectID=41363; RAW_FILE_NAME=VT_160205_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006197_1	Sex:1 | Treatment:1	SubjectID=50230; RAW_FILE_NAME=VT_160205_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002405_1	Sex:2 | Treatment:-	SubjectID=41229; RAW_FILE_NAME=VT_160205_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015321_1	Sex:2 | Treatment:2	SubjectID=50554; RAW_FILE_NAME=VT_160205_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002480_1	Sex:1 | Treatment:2	SubjectID=50880; RAW_FILE_NAME=VT_160205_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002482_1	Sex:2 | Treatment:1	SubjectID=50890; RAW_FILE_NAME=VT_160205_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000733_1	Sex:1 | Treatment:2	SubjectID=50880; RAW_FILE_NAME=VT_160205_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_15b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160205_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106193_1	Sex:2 | Treatment:-	SubjectID=41229; RAW_FILE_NAME=VT_160205_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002462_1	Sex:1 | Treatment:2	SubjectID=50497; RAW_FILE_NAME=VT_160205_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002433_1	Sex:1 | Treatment:1	SubjectID=50230; RAW_FILE_NAME=VT_160205_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000665_1	Sex:1 | Treatment:1	SubjectID=50442; RAW_FILE_NAME=VT_160205_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006085_1	Sex:1 | Treatment:2	SubjectID=50497; RAW_FILE_NAME=VT_160205_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002460_1	Sex:1 | Treatment:-	SubjectID=50486; RAW_FILE_NAME=VT_160205_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000735_1	Sex:2 | Treatment:1	SubjectID=50890; RAW_FILE_NAME=VT_160205_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002416_1	Sex:2 | Treatment:-	SubjectID=41363; RAW_FILE_NAME=VT_160205_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015327_1	Sex:1 | Treatment:1	SubjectID=50475; RAW_FILE_NAME=VT_160205_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002459_1	Sex:1 | Treatment:1	SubjectID=50475; RAW_FILE_NAME=VT_160205_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_15c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160205_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_16a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160206_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002526_1	Sex:1 | Treatment:1	SubjectID=50734; RAW_FILE_NAME=VT_160206_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002522_1	Sex:1 | Treatment:-	SubjectID=50699; RAW_FILE_NAME=VT_160206_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002554_1	Sex:1 | Treatment:-	SubjectID=51208; RAW_FILE_NAME=VT_160206_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002550_1	Sex:1 | Treatment:1	SubjectID=51173; RAW_FILE_NAME=VT_160206_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006202_1	Sex:1 | Treatment:-	SubjectID=50835; RAW_FILE_NAME=VT_160206_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006142_1	Sex:1 | Treatment:2	SubjectID=51219; RAW_FILE_NAME=VT_160206_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000705_1	Sex:1 | Treatment:1	SubjectID=50734; RAW_FILE_NAME=VT_160206_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002546_1	Sex:1 | Treatment:2	SubjectID=51130; RAW_FILE_NAME=VT_160206_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002547_1	Sex:2 | Treatment:-	SubjectID=51151; RAW_FILE_NAME=VT_160206_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002556_1	Sex:1 | Treatment:2	SubjectID=51219; RAW_FILE_NAME=VT_160206_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_16b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160206_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002513_1	Sex:1 | Treatment:2	SubjectID=50622; RAW_FILE_NAME=VT_160206_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002542_1	Sex:1 | Treatment:-	SubjectID=50835; RAW_FILE_NAME=VT_160206_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006237_1	Sex:1 | Treatment:1	SubjectID=51173; RAW_FILE_NAME=VT_160206_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105827_1	Sex:1 | Treatment:-	SubjectID=51208; RAW_FILE_NAME=VT_160206_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106633_1	Sex:1 | Treatment:1	SubjectID=51162; RAW_FILE_NAME=VT_160206_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006051_1	Sex:1 | Treatment:2	SubjectID=50622; RAW_FILE_NAME=VT_160206_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000698_1	Sex:1 | Treatment:-	SubjectID=50699; RAW_FILE_NAME=VT_160206_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105819_1	Sex:1 | Treatment:2	SubjectID=51130; RAW_FILE_NAME=VT_160206_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002549_1	Sex:1 | Treatment:1	SubjectID=51162; RAW_FILE_NAME=VT_160206_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006236_1	Sex:2 | Treatment:-	SubjectID=51151; RAW_FILE_NAME=VT_160206_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_16c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160206_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_17a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160208_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001659_1	Sex:2 | Treatment:1	SubjectID=60050; RAW_FILE_NAME=VT_160208_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002575_1	Sex:1 | Treatment:2	SubjectID=51342; RAW_FILE_NAME=VT_160208_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001006_1	Sex:2 | Treatment:-	SubjectID=30014; RAW_FILE_NAME=VT_160208_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002631_1	Sex:1 | Treatment:1	SubjectID=60689; RAW_FILE_NAME=VT_160208_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001653_1	Sex:1 | Treatment:1	SubjectID=60028; RAW_FILE_NAME=VT_160208_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002591_1	Sex:2 | Treatment:1	SubjectID=60050; RAW_FILE_NAME=VT_160208_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006369_1	Sex:1 | Treatment:2	SubjectID=51400; RAW_FILE_NAME=VT_160208_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002581_1	Sex:1 | Treatment:2	SubjectID=51400; RAW_FILE_NAME=VT_160208_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001651_1	Sex:1 | Treatment:2	SubjectID=51342; RAW_FILE_NAME=VT_160208_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002567_1	Sex:1 | Treatment:1	SubjectID=51285; RAW_FILE_NAME=VT_160208_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_17b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160208_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002588_1	Sex:1 | Treatment:2	SubjectID=60039; RAW_FILE_NAME=VT_160208_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105842_1	Sex:1 | Treatment:1	SubjectID=51285; RAW_FILE_NAME=VT_160208_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002560_1	Sex:2 | Treatment:-	SubjectID=51241; RAW_FILE_NAME=VT_160208_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002585_1	Sex:1 | Treatment:1	SubjectID=60028; RAW_FILE_NAME=VT_160208_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003059_1	Sex:2 | Treatment:-	SubjectID=30014; RAW_FILE_NAME=VT_160208_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001655_1	Sex:1 | Treatment:2	SubjectID=60039; RAW_FILE_NAME=VT_160208_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006432_1	Sex:2 | Treatment:1	SubjectID=51310; RAW_FILE_NAME=VT_160208_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40002751_1	Sex:2 | Treatment:1	SubjectID=51310; RAW_FILE_NAME=VT_160208_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40021552_1	Sex:2 | Treatment:-	SubjectID=51241; RAW_FILE_NAME=VT_160208_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105656_1	Sex:1 | Treatment:1	SubjectID=60689; RAW_FILE_NAME=VT_160208_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_17c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160208_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_18a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160210_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000277_1	Sex:1 | Treatment:1	SubjectID=20731; RAW_FILE_NAME=VT_160210_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003367_1	Sex:1 | Treatment:1	SubjectID=20731; RAW_FILE_NAME=VT_160210_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005529_1	Sex:2 | Treatment:1	SubjectID=20584; RAW_FILE_NAME=VT_160210_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003345_1	Sex:1 | Treatment:1	SubjectID=20551; RAW_FILE_NAME=VT_160210_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003437_1	Sex:1 | Treatment:-	SubjectID=20035; RAW_FILE_NAME=VT_160210_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005456_1	Sex:1 | Treatment:1	SubjectID=20417; RAW_FILE_NAME=VT_160210_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000274_1	Sex:1 | Treatment:-	SubjectID=20709; RAW_FILE_NAME=VT_160210_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000466_1	Sex:1 | Treatment:2	SubjectID=20494; RAW_FILE_NAME=VT_160210_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003331_1	Sex:1 | Treatment:1	SubjectID=20417; RAW_FILE_NAME=VT_160210_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003362_1	Sex:1 | Treatment:-	SubjectID=20709; RAW_FILE_NAME=VT_160210_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_18b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160210_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003339_1	Sex:1 | Treatment:2	SubjectID=20494; RAW_FILE_NAME=VT_160210_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003359_1	Sex:2 | Treatment:1	SubjectID=20630; RAW_FILE_NAME=VT_160210_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000473_1	Sex:1 | Treatment:1	SubjectID=20551; RAW_FILE_NAME=VT_160210_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000490_1	Sex:2 | Treatment:1	SubjectID=20630; RAW_FILE_NAME=VT_160210_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000285_1	Sex:2 | Treatment:2	SubjectID=20797; RAW_FILE_NAME=VT_160210_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003374_1	Sex:2 | Treatment:2	SubjectID=20797; RAW_FILE_NAME=VT_160210_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003336_1	Sex:2 | Treatment:2	SubjectID=20483; RAW_FILE_NAME=VT_160210_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106617_1	Sex:2 | Treatment:2	SubjectID=20483; RAW_FILE_NAME=VT_160210_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000870_1	Sex:1 | Treatment:-	SubjectID=20035; RAW_FILE_NAME=VT_160210_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003350_1	Sex:2 | Treatment:1	SubjectID=20584; RAW_FILE_NAME=VT_160210_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_18c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160210_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_19a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160213_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003483_1	Sex:2 | Treatment:2	SubjectID=11483; RAW_FILE_NAME=VT_160213_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106064_1	Sex:1 | Treatment:1	SubjectID=10370; RAW_FILE_NAME=VT_160213_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000739_1	Sex:1 | Treatment:2	SubjectID=10023; RAW_FILE_NAME=VT_160213_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003452_1	Sex:2 | Treatment:2	SubjectID=20147; RAW_FILE_NAME=VT_160213_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005486_1	Sex:2 | Treatment:2	SubjectID=20147; RAW_FILE_NAME=VT_160213_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003513_1	Sex:1 | Treatment:-	SubjectID=10078; RAW_FILE_NAME=VT_160213_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003462_1	Sex:1 | Treatment:1	SubjectID=20316; RAW_FILE_NAME=VT_160213_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000741_1	Sex:1 | Treatment:1	SubjectID=10034; RAW_FILE_NAME=VT_160213_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003505_1	Sex:1 | Treatment:2	SubjectID=10023; RAW_FILE_NAME=VT_160213_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005564_1	Sex:1 | Treatment:1	SubjectID=20316; RAW_FILE_NAME=VT_160213_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_19b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160213_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003538_1	Sex:1 | Treatment:1	SubjectID=10370; RAW_FILE_NAME=VT_160213_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106701_1	Sex:1 | Treatment:1	SubjectID=10517; RAW_FILE_NAME=VT_160213_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003521_1	Sex:1 | Treatment:2	SubjectID=10157; RAW_FILE_NAME=VT_160213_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015178_1	Sex:2 | Treatment:2	SubjectID=11483; RAW_FILE_NAME=VT_160213_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000749_1	Sex:1 | Treatment:-	SubjectID=10078; RAW_FILE_NAME=VT_160213_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106299_1	Sex:1 | Treatment:2	SubjectID=11507; RAW_FILE_NAME=VT_160213_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003487_1	Sex:1 | Treatment:2	SubjectID=11507; RAW_FILE_NAME=VT_160213_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000759_1	Sex:1 | Treatment:2	SubjectID=10157; RAW_FILE_NAME=VT_160213_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003506_1	Sex:1 | Treatment:1	SubjectID=10034; RAW_FILE_NAME=VT_160213_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003555_1	Sex:1 | Treatment:1	SubjectID=10517; RAW_FILE_NAME=VT_160213_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_19c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160213_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_20a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160214_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106729_1	Sex:2 | Treatment:-	SubjectID=10730; RAW_FILE_NAME=VT_160214_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003635_1	Sex:2 | Treatment:2	SubjectID=21047; RAW_FILE_NAME=VT_160214_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000945_1	Sex:1 | Treatment:2	SubjectID=21192; RAW_FILE_NAME=VT_160214_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003608_1	Sex:1 | Treatment:2	SubjectID=10695; RAW_FILE_NAME=VT_160214_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005601_1	Sex:2 | Treatment:2	SubjectID=21047; RAW_FILE_NAME=VT_160214_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005380_1	Sex:2 | Treatment:-	SubjectID=10673; RAW_FILE_NAME=VT_160214_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005413_1	Sex:1 | Treatment:2	SubjectID=10695; RAW_FILE_NAME=VT_160214_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106711_1	Sex:1 | Treatment:1	SubjectID=10630; RAW_FILE_NAME=VT_160214_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106276_1	Sex:1 | Treatment:-	SubjectID=11327; RAW_FILE_NAME=VT_160214_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005639_1	Sex:2 | Treatment:2	SubjectID=20988; RAW_FILE_NAME=VT_160214_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_20b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160214_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003565_1	Sex:1 | Treatment:1	SubjectID=10630; RAW_FILE_NAME=VT_160214_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106762_1	Sex:2 | Treatment:2	SubjectID=10998; RAW_FILE_NAME=VT_160214_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003597_1	Sex:1 | Treatment:-	SubjectID=11327; RAW_FILE_NAME=VT_160214_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003603_1	Sex:2 | Treatment:-	SubjectID=10673; RAW_FILE_NAME=VT_160214_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003558_1	Sex:1 | Treatment:2	SubjectID=10583; RAW_FILE_NAME=VT_160214_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003627_1	Sex:2 | Treatment:2	SubjectID=20988; RAW_FILE_NAME=VT_160214_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106707_1	Sex:1 | Treatment:2	SubjectID=10583; RAW_FILE_NAME=VT_160214_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003649_1	Sex:1 | Treatment:2	SubjectID=21192; RAW_FILE_NAME=VT_160214_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003566_1	Sex:2 | Treatment:2	SubjectID=10998; RAW_FILE_NAME=VT_160214_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003611_1	Sex:2 | Treatment:-	SubjectID=10730; RAW_FILE_NAME=VT_160214_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_20c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160214_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_21a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160215_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105868_1	Sex:2 | Treatment:1	SubjectID=21282; RAW_FILE_NAME=VT_160215_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005696_1	Sex:1 | Treatment:-	SubjectID=21473; RAW_FILE_NAME=VT_160215_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003662_1	Sex:2 | Treatment:-	SubjectID=21271; RAW_FILE_NAME=VT_160215_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003685_1	Sex:1 | Treatment:-	SubjectID=21430; RAW_FILE_NAME=VT_160215_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007282_1	Sex:2 | Treatment:1	SubjectID=21429; RAW_FILE_NAME=VT_160215_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003683_1	Sex:2 | Treatment:1	SubjectID=21429; RAW_FILE_NAME=VT_160215_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005697_1	Sex:2 | Treatment:-	SubjectID=21451; RAW_FILE_NAME=VT_160215_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003670_1	Sex:1 | Treatment:1	SubjectID=21340; RAW_FILE_NAME=VT_160215_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005628_1	Sex:2 | Treatment:-	SubjectID=21271; RAW_FILE_NAME=VT_160215_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003689_1	Sex:2 | Treatment:-	SubjectID=21451; RAW_FILE_NAME=VT_160215_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_21b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160215_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005631_1	Sex:1 | Treatment:1	SubjectID=21340; RAW_FILE_NAME=VT_160215_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003653_1	Sex:1 | Treatment:-	SubjectID=21216; RAW_FILE_NAME=VT_160215_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105873_1	Sex:1 | Treatment:1	SubjectID=21317; RAW_FILE_NAME=VT_160215_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000339_1	Sex:1 | Treatment:-	SubjectID=21216; RAW_FILE_NAME=VT_160215_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003665_1	Sex:2 | Treatment:1	SubjectID=21282; RAW_FILE_NAME=VT_160215_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003668_1	Sex:1 | Treatment:1	SubjectID=21317; RAW_FILE_NAME=VT_160215_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003691_1	Sex:1 | Treatment:-	SubjectID=21473; RAW_FILE_NAME=VT_160215_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003654_1	Sex:1 | Treatment:-	SubjectID=21227; RAW_FILE_NAME=VT_160215_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005593_1	Sex:1 | Treatment:-	SubjectID=21430; RAW_FILE_NAME=VT_160215_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015101_1	Sex:1 | Treatment:-	SubjectID=21227; RAW_FILE_NAME=VT_160215_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_21c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160215_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_22a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160216_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003733_1	Sex:1 | Treatment:2	SubjectID=21888; RAW_FILE_NAME=VT_160216_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001011_1	Sex:2 | Treatment:2	SubjectID=30047; RAW_FILE_NAME=VT_160216_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005762_1	Sex:2 | Treatment:2	SubjectID=30508; RAW_FILE_NAME=VT_160216_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005970_1	Sex:2 | Treatment:1	SubjectID=30710; RAW_FILE_NAME=VT_160216_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003774_1	Sex:2 | Treatment:-	SubjectID=30238; RAW_FILE_NAME=VT_160216_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003803_1	Sex:2 | Treatment:1	SubjectID=30710; RAW_FILE_NAME=VT_160216_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105607_1	Sex:1 | Treatment:2	SubjectID=30574; RAW_FILE_NAME=VT_160216_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003779_1	Sex:1 | Treatment:-	SubjectID=30340; RAW_FILE_NAME=VT_160216_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001025_1	Sex:2 | Treatment:-	SubjectID=30238; RAW_FILE_NAME=VT_160216_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005726_1	Sex:1 | Treatment:-	SubjectID=30340; RAW_FILE_NAME=VT_160216_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_22b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160216_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003791_1	Sex:1 | Treatment:2	SubjectID=30574; RAW_FILE_NAME=VT_160216_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105906_1	Sex:2 | Treatment:2	SubjectID=21541; RAW_FILE_NAME=VT_160216_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005821_1	Sex:1 | Treatment:-	SubjectID=30732; RAW_FILE_NAME=VT_160216_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003700_1	Sex:2 | Treatment:2	SubjectID=21541; RAW_FILE_NAME=VT_160216_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000991_1	Sex:1 | Treatment:1	SubjectID=21844; RAW_FILE_NAME=VT_160216_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003729_1	Sex:1 | Treatment:1	SubjectID=21844; RAW_FILE_NAME=VT_160216_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003806_1	Sex:2 | Treatment:2	SubjectID=30508; RAW_FILE_NAME=VT_160216_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105513_1	Sex:1 | Treatment:2	SubjectID=21888; RAW_FILE_NAME=VT_160216_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003805_1	Sex:1 | Treatment:-	SubjectID=30732; RAW_FILE_NAME=VT_160216_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003761_1	Sex:2 | Treatment:2	SubjectID=30047; RAW_FILE_NAME=VT_160216_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_22c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160216_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_23a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160217_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015624_1	Sex:1 | Treatment:1	SubjectID=30989; RAW_FILE_NAME=VT_160217_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005426_1	Sex:1 | Treatment:-	SubjectID=11191; RAW_FILE_NAME=VT_160217_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003824_1	Sex:1 | Treatment:1	SubjectID=30989; RAW_FILE_NAME=VT_160217_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005402_1	Sex:1 | Treatment:1	SubjectID=11281; RAW_FILE_NAME=VT_160217_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005399_1	Sex:2 | Treatment:2	SubjectID=10629; RAW_FILE_NAME=VT_160217_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000750_1	Sex:1 | Treatment:-	SubjectID=10089; RAW_FILE_NAME=VT_160217_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005331_1	Sex:1 | Treatment:-	SubjectID=10607; RAW_FILE_NAME=VT_160217_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005504_1	Sex:2 | Treatment:2	SubjectID=20204; RAW_FILE_NAME=VT_160217_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40003807_1	Sex:2 | Treatment:1	SubjectID=30776; RAW_FILE_NAME=VT_160217_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000799_1	Sex:1 | Treatment:-	SubjectID=10607; RAW_FILE_NAME=VT_160217_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_23b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160217_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000838_1	Sex:1 | Treatment:-	SubjectID=11191; RAW_FILE_NAME=VT_160217_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005822_1	Sex:2 | Treatment:1	SubjectID=30776; RAW_FILE_NAME=VT_160217_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106758_1	Sex:1 | Treatment:1	SubjectID=10965; RAW_FILE_NAME=VT_160217_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005296_1	Sex:1 | Treatment:1	SubjectID=10405; RAW_FILE_NAME=VT_160217_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005376_1	Sex:1 | Treatment:1	SubjectID=10965; RAW_FILE_NAME=VT_160217_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106068_1	Sex:1 | Treatment:1	SubjectID=10405; RAW_FILE_NAME=VT_160217_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000801_1	Sex:2 | Treatment:2	SubjectID=10629; RAW_FILE_NAME=VT_160217_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015065_1	Sex:1 | Treatment:1	SubjectID=11281; RAW_FILE_NAME=VT_160217_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005328_1	Sex:1 | Treatment:-	SubjectID=10089; RAW_FILE_NAME=VT_160217_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000431_1	Sex:2 | Treatment:2	SubjectID=20204; RAW_FILE_NAME=VT_160217_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_23c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160217_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_24a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160218_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000475_1	Sex:1 | Treatment:2	SubjectID=20562; RAW_FILE_NAME=VT_160218_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005621_1	Sex:1 | Treatment:2	SubjectID=21238; RAW_FILE_NAME=VT_160218_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106611_1	Sex:2 | Treatment:2	SubjectID=21025; RAW_FILE_NAME=VT_160218_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105567_1	Sex:1 | Treatment:1	SubjectID=30271; RAW_FILE_NAME=VT_160218_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005573_1	Sex:1 | Treatment:2	SubjectID=20562; RAW_FILE_NAME=VT_160218_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000276_1	Sex:1 | Treatment:2	SubjectID=20710; RAW_FILE_NAME=VT_160218_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005642_1	Sex:1 | Treatment:1	SubjectID=21104; RAW_FILE_NAME=VT_160218_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005549_1	Sex:1 | Treatment:2	SubjectID=20710; RAW_FILE_NAME=VT_160218_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005574_1	Sex:1 | Treatment:-	SubjectID=20608; RAW_FILE_NAME=VT_160218_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005605_1	Sex:1 | Treatment:2	SubjectID=21238; RAW_FILE_NAME=VT_160218_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_24b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160218_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000330_1	Sex:1 | Treatment:1	SubjectID=21104; RAW_FILE_NAME=VT_160218_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000299_1	Sex:2 | Treatment:1	SubjectID=20900; RAW_FILE_NAME=VT_160218_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005741_1	Sex:1 | Treatment:1	SubjectID=30271; RAW_FILE_NAME=VT_160218_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005777_1	Sex:1 | Treatment:2	SubjectID=30070; RAW_FILE_NAME=VT_160218_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106284_1	Sex:1 | Treatment:-	SubjectID=11360; RAW_FILE_NAME=VT_160218_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001013_1	Sex:1 | Treatment:2	SubjectID=30070; RAW_FILE_NAME=VT_160218_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005615_1	Sex:2 | Treatment:1	SubjectID=20900; RAW_FILE_NAME=VT_160218_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000483_1	Sex:1 | Treatment:-	SubjectID=20608; RAW_FILE_NAME=VT_160218_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005513_1	Sex:1 | Treatment:-	SubjectID=11360; RAW_FILE_NAME=VT_160218_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005617_1	Sex:2 | Treatment:2	SubjectID=21025; RAW_FILE_NAME=VT_160218_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_24c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160218_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_25a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160220_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005902_1	Sex:2 | Treatment:2	SubjectID=40048; RAW_FILE_NAME=VT_160220_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005871_1	Sex:1 | Treatment:1	SubjectID=40362; RAW_FILE_NAME=VT_160220_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005781_1	Sex:1 | Treatment:2	SubjectID=21675; RAW_FILE_NAME=VT_160220_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005785_1	Sex:1 | Treatment:1	SubjectID=21956; RAW_FILE_NAME=VT_160220_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005779_1	Sex:2 | Treatment:2	SubjectID=30383; RAW_FILE_NAME=VT_160220_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005818_1	Sex:1 | Treatment:-	SubjectID=30754; RAW_FILE_NAME=VT_160220_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005768_1	Sex:1 | Treatment:1	SubjectID=21956; RAW_FILE_NAME=VT_160220_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005783_1	Sex:1 | Treatment:1	SubjectID=21811; RAW_FILE_NAME=VT_160220_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005763_1	Sex:1 | Treatment:2	SubjectID=21675; RAW_FILE_NAME=VT_160220_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005854_1	Sex:1 | Treatment:1	SubjectID=40362; RAW_FILE_NAME=VT_160220_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_25b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160220_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105626_1	Sex:2 | Treatment:2	SubjectID=30721; RAW_FILE_NAME=VT_160220_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105503_1	Sex:1 | Treatment:1	SubjectID=21811; RAW_FILE_NAME=VT_160220_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015684_1	Sex:1 | Treatment:-	SubjectID=30754; RAW_FILE_NAME=VT_160220_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005855_1	Sex:1 | Treatment:1	SubjectID=40408; RAW_FILE_NAME=VT_160220_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005846_1	Sex:1 | Treatment:1	SubjectID=30260; RAW_FILE_NAME=VT_160220_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005872_1	Sex:1 | Treatment:1	SubjectID=40408; RAW_FILE_NAME=VT_160220_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005761_1	Sex:2 | Treatment:2	SubjectID=30383; RAW_FILE_NAME=VT_160220_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005832_1	Sex:1 | Treatment:1	SubjectID=30260; RAW_FILE_NAME=VT_160220_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001410_1	Sex:2 | Treatment:2	SubjectID=40048; RAW_FILE_NAME=VT_160220_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005878_1	Sex:2 | Treatment:2	SubjectID=30721; RAW_FILE_NAME=VT_160220_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_25c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160220_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_26a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160222_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40016058_1	Sex:1 | Treatment:2	SubjectID=41486; RAW_FILE_NAME=VT_160222_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001498_1	Sex:1 | Treatment:2	SubjectID=41106; RAW_FILE_NAME=VT_160222_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006107_1	Sex:1 | Treatment:2	SubjectID=40520; RAW_FILE_NAME=VT_160222_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005923_1	Sex:1 | Treatment:2	SubjectID=41486; RAW_FILE_NAME=VT_160222_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000397_1	Sex:1 | Treatment:1	SubjectID=40990; RAW_FILE_NAME=VT_160222_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006008_1	Sex:1 | Treatment:1	SubjectID=31026; RAW_FILE_NAME=VT_160222_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001408_1	Sex:1 | Treatment:1	SubjectID=40037; RAW_FILE_NAME=VT_160222_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000658_1	Sex:1 | Treatment:2	SubjectID=40520; RAW_FILE_NAME=VT_160222_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006045_1	Sex:1 | Treatment:-	SubjectID=41218; RAW_FILE_NAME=VT_160222_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000374_1	Sex:1 | Treatment:1	SubjectID=40812; RAW_FILE_NAME=VT_160222_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_26b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160222_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006015_1	Sex:1 | Treatment:1	SubjectID=40812; RAW_FILE_NAME=VT_160222_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006080_1	Sex:2 | Treatment:-	SubjectID=41284; RAW_FILE_NAME=VT_160222_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006043_1	Sex:1 | Treatment:1	SubjectID=40037; RAW_FILE_NAME=VT_160222_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015702_1	Sex:1 | Treatment:1	SubjectID=31026; RAW_FILE_NAME=VT_160222_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006112_1	Sex:1 | Treatment:2	SubjectID=41106; RAW_FILE_NAME=VT_160222_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005985_1	Sex:1 | Treatment:-	SubjectID=41218; RAW_FILE_NAME=VT_160222_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000617_1	Sex:2 | Treatment:-	SubjectID=40240; RAW_FILE_NAME=VT_160222_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005997_1	Sex:1 | Treatment:1	SubjectID=40990; RAW_FILE_NAME=VT_160222_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006102_1	Sex:2 | Treatment:-	SubjectID=41284; RAW_FILE_NAME=VT_160222_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005930_1	Sex:2 | Treatment:-	SubjectID=40240; RAW_FILE_NAME=VT_160222_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_26c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160222_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_27a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160223_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006161_1	Sex:1 | Treatment:-	SubjectID=50284; RAW_FILE_NAME=VT_160223_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40014530_1	Sex:1 | Treatment:-	SubjectID=50251; RAW_FILE_NAME=VT_160223_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006272_1	Sex:2 | Treatment:1	SubjectID=50756; RAW_FILE_NAME=VT_160223_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105830_1	Sex:1 | Treatment:-	SubjectID=51220; RAW_FILE_NAME=VT_160223_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006327_1	Sex:1 | Treatment:-	SubjectID=60375; RAW_FILE_NAME=VT_160223_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006438_1	Sex:1 | Treatment:-	SubjectID=60645; RAW_FILE_NAME=VT_160223_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006245_1	Sex:1 | Treatment:-	SubjectID=51220; RAW_FILE_NAME=VT_160223_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105774_1	Sex:1 | Treatment:1	SubjectID=60454; RAW_FILE_NAME=VT_160223_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006147_1	Sex:1 | Treatment:-	SubjectID=50284; RAW_FILE_NAME=VT_160223_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006540_1	Sex:2 | Treatment:2	SubjectID=60904; RAW_FILE_NAME=VT_160223_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_27b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160223_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006233_1	Sex:2 | Treatment:-	SubjectID=50969; RAW_FILE_NAME=VT_160223_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006216_1	Sex:2 | Treatment:-	SubjectID=50969; RAW_FILE_NAME=VT_160223_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006211_1	Sex:2 | Treatment:2	SubjectID=41790; RAW_FILE_NAME=VT_160223_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006519_1	Sex:1 | Treatment:1	SubjectID=60454; RAW_FILE_NAME=VT_160223_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106472_1	Sex:2 | Treatment:2	SubjectID=41790; RAW_FILE_NAME=VT_160223_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006422_1	Sex:1 | Treatment:-	SubjectID=60645; RAW_FILE_NAME=VT_160223_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001696_1	Sex:1 | Treatment:-	SubjectID=60375; RAW_FILE_NAME=VT_160223_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006523_1	Sex:2 | Treatment:2	SubjectID=60904; RAW_FILE_NAME=VT_160223_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006286_1	Sex:2 | Treatment:1	SubjectID=50756; RAW_FILE_NAME=VT_160223_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006120_1	Sex:1 | Treatment:-	SubjectID=50251; RAW_FILE_NAME=VT_160223_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_27c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160223_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_28a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160224_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000218_1	Sex:1 | Treatment:-	SubjectID=71085; RAW_FILE_NAME=VT_160224_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106515_1	Sex:1 | Treatment:-	SubjectID=50295; RAW_FILE_NAME=VT_160224_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015871_1	Sex:1 | Treatment:2	SubjectID=90514; RAW_FILE_NAME=VT_160224_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006854_1	Sex:1 | Treatment:-	SubjectID=90277; RAW_FILE_NAME=VT_160224_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000565_1	Sex:1 | Treatment:-	SubjectID=90200; RAW_FILE_NAME=VT_160224_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006786_1	Sex:2 | Treatment:-	SubjectID=41734; RAW_FILE_NAME=VT_160224_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006773_1	Sex:1 | Treatment:-	SubjectID=50295; RAW_FILE_NAME=VT_160224_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006802_1	Sex:2 | Treatment:2	SubjectID=50778; RAW_FILE_NAME=VT_160224_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006818_1	Sex:1 | Treatment:1	SubjectID=41756; RAW_FILE_NAME=VT_160224_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006624_1	Sex:1 | Treatment:-	SubjectID=70590; RAW_FILE_NAME=VT_160224_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_28b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160224_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006873_1	Sex:1 | Treatment:-	SubjectID=90277; RAW_FILE_NAME=VT_160224_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006820_1	Sex:2 | Treatment:1	SubjectID=41633; RAW_FILE_NAME=VT_160224_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006768_1	Sex:2 | Treatment:-	SubjectID=41734; RAW_FILE_NAME=VT_160224_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106248_1	Sex:2 | Treatment:1	SubjectID=41633; RAW_FILE_NAME=VT_160224_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006905_1	Sex:1 | Treatment:2	SubjectID=90514; RAW_FILE_NAME=VT_160224_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006650_1	Sex:1 | Treatment:-	SubjectID=70590; RAW_FILE_NAME=VT_160224_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006649_1	Sex:1 | Treatment:-	SubjectID=71085; RAW_FILE_NAME=VT_160224_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015457_1	Sex:1 | Treatment:1	SubjectID=41756; RAW_FILE_NAME=VT_160224_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006814_1	Sex:2 | Treatment:2	SubjectID=50778; RAW_FILE_NAME=VT_160224_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006736_1	Sex:1 | Treatment:-	SubjectID=90200; RAW_FILE_NAME=VT_160224_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_28c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160224_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_29a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160225_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007173_1	Sex:1 | Treatment:1	SubjectID=21912; RAW_FILE_NAME=VT_160225_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015231_1	Sex:1 | Treatment:2	SubjectID=91098; RAW_FILE_NAME=VT_160225_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007009_1	Sex:1 | Treatment:-	SubjectID=91111; RAW_FILE_NAME=VT_160225_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106158_1	Sex:1 | Treatment:1	SubjectID=90806; RAW_FILE_NAME=VT_160225_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007065_1	Sex:1 | Treatment:-	SubjectID=91256; RAW_FILE_NAME=VT_160225_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005355_1	Sex:1 | Treatment:2	SubjectID=11024; RAW_FILE_NAME=VT_160225_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007164_1	Sex:1 | Treatment:1	SubjectID=90806; RAW_FILE_NAME=VT_160225_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007033_1	Sex:1 | Treatment:2	SubjectID=91098; RAW_FILE_NAME=VT_160225_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007078_1	Sex:1 | Treatment:-	SubjectID=91256; RAW_FILE_NAME=VT_160225_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007132_1	Sex:1 | Treatment:1	SubjectID=21912; RAW_FILE_NAME=VT_160225_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_29b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160225_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006983_1	Sex:1 | Treatment:-	SubjectID=91111; RAW_FILE_NAME=VT_160225_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007098_1	Sex:1 | Treatment:1	SubjectID=91537; RAW_FILE_NAME=VT_160225_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007138_1	Sex:1 | Treatment:-	SubjectID=10720; RAW_FILE_NAME=VT_160225_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007113_1	Sex:1 | Treatment:2	SubjectID=91480; RAW_FILE_NAME=VT_160225_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106576_1	Sex:1 | Treatment:1	SubjectID=91537; RAW_FILE_NAME=VT_160225_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007021_1	Sex:1 | Treatment:2	SubjectID=91087; RAW_FILE_NAME=VT_160225_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007041_1	Sex:1 | Treatment:2	SubjectID=91087; RAW_FILE_NAME=VT_160225_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015434_1	Sex:1 | Treatment:-	SubjectID=10720; RAW_FILE_NAME=VT_160225_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007140_1	Sex:1 | Treatment:2	SubjectID=11024; RAW_FILE_NAME=VT_160225_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40007101_1	Sex:1 | Treatment:2	SubjectID=91480; RAW_FILE_NAME=VT_160225_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_29c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160225_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_30a_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160226_001
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022359_1	Sex:1 | Treatment:-	SubjectID=50172; RAW_FILE_NAME=VT_160226_007
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40014517_1	Sex:1 | Treatment:-	SubjectID=10090; RAW_FILE_NAME=VT_160226_013
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105900_1	Sex:1 | Treatment:1	SubjectID=21519; RAW_FILE_NAME=VT_160226_019
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022876_1	Sex:1 | Treatment:1	SubjectID=21519; RAW_FILE_NAME=VT_160226_025
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105724_1	Sex:1 | Treatment:-	SubjectID=60118; RAW_FILE_NAME=VT_160226_031
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001569_1	Sex:1 | Treatment:1	SubjectID=50117; RAW_FILE_NAME=VT_160226_037
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022468_1	Sex:1 | Treatment:1	SubjectID=50117; RAW_FILE_NAME=VT_160226_043
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40015971_1	Sex:1 | Treatment:2	SubjectID=70321; RAW_FILE_NAME=VT_160226_049
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022495_1	Sex:1 | Treatment:2	SubjectID=40250; RAW_FILE_NAME=VT_160226_055
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022374_1	Sex:1 | Treatment:2	SubjectID=60432; RAW_FILE_NAME=VT_160226_061
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_30b_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160226_067
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40006789_1	Sex:1 | Treatment:-	SubjectID=50172; RAW_FILE_NAME=VT_160226_073
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40001440_1	Sex:1 | Treatment:2	SubjectID=40250; RAW_FILE_NAME=VT_160226_079
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022363_1	Sex:2 | Treatment:-	SubjectID=20270; RAW_FILE_NAME=VT_160226_085
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022384_1	Sex:2 | Treatment:1	SubjectID=30350; RAW_FILE_NAME=VT_160226_091
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400106024_1	Sex:1 | Treatment:-	SubjectID=10090; RAW_FILE_NAME=VT_160226_097
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022734_1	Sex:1 | Treatment:2	SubjectID=70321; RAW_FILE_NAME=VT_160226_103
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40022462_1	Sex:1 | Treatment:-	SubjectID=60118; RAW_FILE_NAME=VT_160226_109
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40005890_1	Sex:2 | Treatment:1	SubjectID=30350; RAW_FILE_NAME=VT_160226_115
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	400105771_1	Sex:1 | Treatment:2	SubjectID=60432; RAW_FILE_NAME=VT_160226_121
SUBJECT_SAMPLE_FACTORS           	Plasma Study Sample	40000892_1	Sex:2 | Treatment:-	SubjectID=20270; RAW_FILE_NAME=VT_160226_127
SUBJECT_SAMPLE_FACTORS           	Quality Control	q3June2014_30c_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160226_133
SUBJECT_SAMPLE_FACTORS           	Quality Control	nist2_1	Sex:NA | Treatment:NA	SubjectID=NA; RAW_FILE_NAME=VT_160226_139
#COLLECTION
CO:COLLECTION_SUMMARY            	Blood plasma samples were collected from non-fasting participants in the
CO:COLLECTION_SUMMARY            	Aspirin/Folate Polyp Prevention Study at enrollment (baseline) and after three
CO:COLLECTION_SUMMARY            	years of study treatment. Blood samples were collected in tubes containing EDTA
CO:COLLECTION_SUMMARY            	and after centrifugation aliquots of plasma were transferred to 1.8ml freezer
CO:COLLECTION_SUMMARY            	tubes and stored frozen at -20C or lower. The samples were shipped on dry ice
CO:COLLECTION_SUMMARY            	from the clinical centers to the Dartmouth biorepository storage facility (for
CO:COLLECTION_SUMMARY            	storage at -70C) and subsequently to the metabolimics analysis lab at Emory
CO:COLLECTION_SUMMARY            	University.
CO:SAMPLE_TYPE                   	Blood (plasma)
CO:STORAGE_CONDITIONS            	Described in summary
#TREATMENT
TR:TREATMENT_SUMMARY             	Samples were received frozen in aliquouts of <250uL. Prior to analysis, samples
TR:TREATMENT_SUMMARY             	were thawed and prepared for HRM analysis using the standard protocols described
TR:TREATMENT_SUMMARY             	in the Sample Preparation section.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Samples were prepared for metabolomics analysis using established
SP:SAMPLEPREP_SUMMARY            	methods(Johnson et al. (2010). Analyst; Go et al. (2015). Tox Sci). Prior to
SP:SAMPLEPREP_SUMMARY            	analysis, plasma aliquots were removed from storage at -80 degrees C and thawed
SP:SAMPLEPREP_SUMMARY            	on ice. Each cryotube was then vortexed briefly to ensure homogeneity, and 50
SP:SAMPLEPREP_SUMMARY            	microliters was transferred to a clean microfuge tube. Immediately after, the
SP:SAMPLEPREP_SUMMARY            	plasma was treated with 100 microliters of ice-cold LC-MS grade acetonitrile
SP:SAMPLEPREP_SUMMARY            	(Sigma Aldrich) containing 2.5 microliters of internal standard solution with
SP:SAMPLEPREP_SUMMARY            	eight stable isotopic chemicals selected to cover a range of chemical
SP:SAMPLEPREP_SUMMARY            	properties. Following addition of acetonitrile, urine was equilibrated for 30min
SP:SAMPLEPREP_SUMMARY            	on ice, upon which precipitated proteins were removed by centrifuge (14,000rpm
SP:SAMPLEPREP_SUMMARY            	at 4 degrees C for 10 min). The resulting supernatant (100 microliters) was
SP:SAMPLEPREP_SUMMARY            	removed, added to a low volume autosampler vial and maintained at 4 degrees C
SP:SAMPLEPREP_SUMMARY            	until analysis (<22 h).
SP:SAMPLEPREP_PROTOCOL_ID        	HRM_SP_082016_01
SP:SAMPLEPREP_PROTOCOL_FILENAME  	EmoryUniversity_HRM_SP_082016_01.pdf
SP:SAMPLEPREP_PROTOCOL_COMMENTS  	Date effective: 30 July 2016
SP:EXTRACTION_METHOD             	2:1 acetonitrile: sample followed by vortexing and centrifugation
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	The C18 column is operated parallel to the HILIC column for simultaneous
CH:CHROMATOGRAPHY_SUMMARY        	analytical separation and column flushing through the use of a dual head HPLC
CH:CHROMATOGRAPHY_SUMMARY        	pump equipped with 10-port and 6- port switching valves. During operation of the
CH:CHROMATOGRAPHY_SUMMARY        	C18 method, the MS is operated in negative ion mode and 10 uL of sample is
CH:CHROMATOGRAPHY_SUMMARY        	injected onto the C18 column while the HILIC column is flushing with wash
CH:CHROMATOGRAPHY_SUMMARY        	solution. Flow rate is maintained at 0.35 mL/min until 2 min, increased to 0.4
CH:CHROMATOGRAPHY_SUMMARY        	mL/min at 6 min and held for 4 min. Solvent A is 100% LC-MS grade water, solvent
CH:CHROMATOGRAPHY_SUMMARY        	B is 100% LC-MS grade acetonitrile and solvent C is 2% formic acid (v/v) in
CH:CHROMATOGRAPHY_SUMMARY        	LC-MS grade water. Initial mobile phase conditions are 80% A, 15% B, 5% C hold
CH:CHROMATOGRAPHY_SUMMARY        	for 0.5 min, with linear gradient to 0% A, 95% B, 5% C at 2 min, hold for 4min,
CH:CHROMATOGRAPHY_SUMMARY        	resulting in a total analytical run time of 10 min. During the flushing phase
CH:CHROMATOGRAPHY_SUMMARY        	(HILIC analytical separation), the C18 column is equilibrated with a wash
CH:CHROMATOGRAPHY_SUMMARY        	solution of 0% A, 95% B, 5% C until 7.5 min, followed by an equilibration
CH:CHROMATOGRAPHY_SUMMARY        	solution of 80% A, 15% B, 5% C for 2.5 min.
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Dionex UltiMate 3000
CH:COLUMN_NAME                   	Thermo Fisher Accucore C18 50x2.1mm 2.6u with Thermo accucore
CH:FLOW_RATE                     	0.35 mL/min for 2 min; linear increase to 0.4 mL/min at 6 min held for 4 min
CH:COLUMN_TEMPERATURE            	60C
CH:METHODS_FILENAME              	20160120_posC18120kres10mim_ESI_hilicposwash_acore.meth
CH:SOLVENT_A                     	LC-MS grade water
CH:SOLVENT_B                     	LC-MS grade acetonitrile
CH:SAMPLE_INJECTION              	10 uL
CH:ANALYTICAL_TIME               	10 min
CH:SAMPLE_LOOP_SIZE              	15 uL
CH:SAMPLE_SYRINGE_SIZE           	100 uL
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:LABORATORY_NAME               	Clinical Biomarkers Laboratory
AN:OPERATOR_NAME                 	Vilinh Tran
AN:DETECTOR_TYPE                 	Orbitrap
AN:SOFTWARE_VERSION              	Xcalibur 3.0.63
AN:ACQUISITION_DATE              	1/20/16-2/26/16
AN:ANALYSIS_PROTOCOL_FILE        	EmoryUniversity_HRM_QEHF-MS_092017_v1.pdf
AN:DATA_FORMAT                   	Profile
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive HF hybrid Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	None
MS:CAPILLARY_TEMPERATURE         	250C
MS:COLLISION_GAS                 	N2
MS:DRY_GAS_FLOW                  	45
MS:DRY_GAS_TEMP                  	150C
MS:MASS_ACCURACY                 	< 3ppm
MS:SPRAY_VOLTAGE                 	-4000
MS:ACTIVATION_PARAMETER          	5.00E+05
MS:ACTIVATION_TIME               	118ms
MS:INTERFACE_VOLTAGE             	S-Lens RF level= 55
MS:MS_RESULTS_FILE               	ST001422_AN002379_Results.txt	UNITS:peak area	Has m/z:Yes	Has RT:Yes	RT units:Seconds
#END